SOUTH SAN FRANCISCO, Calif., Jan. 5 /PRNewswire-FirstCall/ -- Anesiva, Inc. will host a webcast conference call on Monday, January 8, 2007 at 9:00 a.m. Eastern Time. Anesiva recently completed a successful meeting with the FDA regarding its clinical plan for 4975, the company's novel, long-acting, non-opioid drug candidate being developed for site- specific, moderate-to-severe pain, and members of Anesiva's management team plan to review the plan on the webcast call.
Interested parties can listen to the live audio webcast by dialing 800-340-6289 (international dial: +1-706-634-1538 or by logging on to www.anesiva.com and going to the Investor Information page. Please connect to Anesiva's website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary. For those unable to listen to the live conference call or to access the call via the internet, a 24-hour dial-in replay will be available for seven days after the call by dialing 800-642-1687 (international dial: +1-706-645-9291) and giving the following pass code: 5711122.
About Anesiva and its Diverse Pipeline of Pain Products
Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has three drug candidates in development for multiple pain-related indications. A New Drug Application (NDA) has been submitted for the most advanced product, Zingo(TM). The second product in the pipeline, 4975, has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, moderate-to-severe pain. A third product, 1207, is currently being evaluated in a Phase 1 clinical trial as a topical local anesthetic. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to www.anesiva.com .
Anesiva, Inc.CONTACT: Jennifer Cook Williams, Vice President, Investor Relations ofAnesiva, Inc., +1-650-624-9600, or investors@anesiva.com
Web site: http://www.anesiva.com/
